Tempus
Amount not stated
Commercialization and reference laboratory agreement under which Tempus markets NeXT Personal Dx in the United States
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.
Commercialization and reference laboratory agreement under which Tempus markets NeXT Personal Dx in the United States
Development activity fees Tempus agreed to pay us under the Tempus Agreement
Co-promotion arrangement under which we compensate Tempus for promotional and commercialization services
Amendment extending the Tempus Agreement term and adding a fourth indication
Tempus Warrants to purchase 4,609,400 shares at $1.50 and 4,609,400 shares at $2.50 issued as partial consideration under the Tempus Agreement
Exercise in full of the Tempus Warrants for 9,218,800 shares
Sale of 3,500,000 shares of our common stock to Tempus under the Tempus Investment Agreement
Sale of 14,044,943 shares of our common stock to Merck under the Merck Investment Agreement
Master Service Agreement under which Merck engaged us for DNA and RNA sequencing, data interpretation, compound synthesis and analysis services, amended in February 2024 to add clinical laboratory services
Genomic testing services invoiced to Merck under the Master Agreement
Loading...
